Physician profile
Sanjay Lodha
NPI 1265595300
$3,863.62
in general payments reported to CMS, 2019-2025
28 companies · $853 in 2025
The $853 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $241 · 2021: $382 · 2022: $512 · 2023: $557 · 2024: $950 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $960.96 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $645.21 | 2023-2025 | Tepezza, Repatha, Otezla |
| Novo Nordisk INC | $333.35 | 2022-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $306.34 | 2019-2024 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $265.40 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $198.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $190.46 | 2019-2023 | |
| Ucb, INC. | $117.07 | 2020-2021 | |
| Dexcom, INC. | $113.34 | 2019 | |
| Intuity Medical INC | $105.62 | 2022 | |
| Sunovion Pharmaceuticals INC. | $81.08 | 2019 | |
| Astellas Pharma US INC | $73.53 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $63.44 | 2024 | Rexulti |
| Amarin Pharma, INC. | $61.61 | 2021 | |
| Abbott Laboratories | $56.98 | 2021-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.63 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $36.18 | 2022-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $28.63 | 2025 | Voquezna |
| Radius Health, INC. | $23.50 | 2020 | |
| Acadia Pharmaceuticals INC | $22.26 | 2022 | |
| Lundbeck LLC | $21.72 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $20.95 | 2021 | |
| Mylan Specialty L.P. | $18.69 | 2023 | Yupelri |
| Viatris Specialty LLC | $18.22 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.04 | 2019 | |
| Bavarian Nordic A/S | $15.22 | 2025 | Vivotif |
| Kowa Pharmaceuticals America, INC. | $15.17 | 2021 | |
| Pfizer INC. | $13.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Lodha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.